|
1
|
Marech I, Vacca A, Ranieri G, Gnoni A and
Dammacco F: Novel strategies in the treatment of
castration-resistant prostate cancer (Review). Int J Oncol.
40:1313–1320. 2012.PubMed/NCBI
|
|
2
|
Nacusi LP and Tindall DJ: Targeting
5α-reductase for prostate cancer prevention and treatment. Nat Rev
Urol. 8:378–384. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Locke JA, Guns ES, Lubik AA, Adomat HH,
Hendy SC, Wood CA, Ettinger SL, Gleave ME and Nelson CC: Androgen
levels increase by intratumoral de novo steroidogenesis during
progression of castration-resistant prostate cancer. Cancer Res.
68:6407–6415. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Montgomery RB, Mostaghel EA, Vessella R,
Hess DL, Kalhorn TF, Higano CS, True LD and Nelson PS: Maintenance
of intratumoral androgens in metastatic prostate cancer: A
mechanism for castration-resistant tumor growth. Cancer Res.
68:4447–4454. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stanbrough M, Bubley GJ, Ross K, Golub TR,
Rubin MA, Penning TM, Febbo PG and Balk SP: Increased expression of
genes converting adrenal androgens to testosterone in
androgen-independent prostate cancer. Cancer Res. 66:2815–2825.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Geller J, Albert JD, Nachtsheim DA and
Loza D: Comparison of prostatic cancer tissue dihydrotestosterone
levels at the time of relapse following orchiectomy or estrogen
therapy. J Urol. 132:693–696. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mohler JL, Gregory CW, Ford OH III, Kim D,
Weaver CM, Petrusz P, Wilson EM and French FS: The androgen axis in
recurrent prostate cancer. Clin Cancer Res. 10:440–448. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Titus MA, Schell MJ, Lih FB, Tomer KB and
Mohler JL: Testosterone and dihydrotestosterone tissue levels in
recurrent prostate cancer. Clin Cancer Res. 11:4653–4657. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mostaghel EA, Page ST, Lin DW, Fazli L,
Coleman IM, True LD, Knudsen B, Hess DL, Nelson CC, Matsumoto AM,
et al: Intraprostatic androgens and androgen-regulated gene
expression persist after testosterone suppression: Therapeutic
implications for castration-resistant prostate cancer. Cancer Res.
67:5033–5041. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gleave ME, La Bianca S and Goldenberg SL:
Neoadjuvant hormonal therapy prior to radical prostatectomy:
Promises and pitfalls. Prostate Cancer Prostatic Dis. 3:136–144.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ryan CJ, Smith MR, de Bono JS, Molina A,
Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng
S, et al: Abiraterone in metastatic prostate cancer without
previous chemotherapy. N Engl J Med. 368:138–148. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Scher HI, Fizazi K, Saad F, Taplin ME,
Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, et
al: Increased survival with enzalutamide in prostate cancer after
chemotherapy. N Engl J Med. 367:1187–1197. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yin L and Hu Q: CYP17
inhibitors-abiraterone, C17,20-lyase inhibitors and multi-targeting
agents. Nat Rev Urol. 11:32–42. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Uemura M, Tamura K, Chung S, Honma S,
Okuyama A, Nakamura Y and Nakagawa H: Novel 5 alpha-steroid
reductase (SRD5A3, type-3) is overexpressed in hormone-refractory
prostate cancer. Cancer Sci. 99:81–86. 2008.PubMed/NCBI
|
|
15
|
Chang KH, Li R, Papari-Zareei M, Watumull
L, Zhao YD, Auchus RJ and Sharifi N: Dihydrotestosterone synthesis
bypasses testosterone to drive castration-resistant prostate
cancer. Proc Natl Acad Sci USA. 108:pp. 13728–13733. 2011;
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Andriole GL, Bostwick DG, Brawley OW,
Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL,
Teloken C, Tindall DJ, et al: Effect of dutasteride on the risk of
prostate cancer. N Engl J Med. 362:1192–1202. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Barkin J, Guimaraes M, Jacobi G, Pushkar
D, Taylor S and van Vierssen Trip OB: Alpha-blocker therapy can be
withdrawn in the majority of men following initial combination
therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur
Urol. 44:461–466. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tindall DJ and Rittmaster RS: The
rationale for inhibiting 5alpha-reductase isoenzymes in the
prevention and treatment of prostate cancer. J Urol. 179:1235–1242.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Petrylak DP, Macarthur RB, O'Connor J,
Shelton G, Judge T, Balog J, Pfaff C, Bagiella E, Heitjan D, Fine
R, et al: Phase I trial of docetaxel with estramustine in
androgen-independent prostate cancer. J Clin Oncol. 17:958–967.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sella A, Sternberg CN, Skoneczna I and
Kovel S: Prostate-specific antigen flare phenomenon with
docetaxel-based chemotherapy in patients with androgen-independent
prostate cancer. BJU Int. 102:1607–1609. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sartor O, Nakabayashi M, Taplin ME, Ross
RW, Kantoff PW, Balk SP and Oh WK: Activity of dutasteride plus
ketoconazole in castration-refractory prostate cancer after
progression on ketoconazole alone. Clin Genitourin Cancer.
7:E90–E92. 2009. View Article : Google Scholar : PubMed/NCBI
|
